1. Navigating the U.S. regulatory landscape for neurologic digital health technologies.
- Author
-
Busis, Neil A., Marolia, Dilshad, Montgomery, Robert, Balcer, Laura J., Galetta, Steven L., and Grossman, Scott N.
- Subjects
DIGITAL technology ,POLICY sciences ,CLINICAL medicine ,NATURE ,PATIENT safety ,DIGITAL health ,MEDICAL care ,ARTIFICIAL intelligence ,EYE movement measurements ,EVALUATION of medical care - Abstract
Digital health technologies (DHTs) can transform neurological assessments, improving quality and continuity of care. In the United States, the Food & Drug Administration (FDA) oversees the safety and efficacy of these technologies, employing a detailed regulatory process that classifies devices based on risk and requires rigorous review and post-market surveillance. Following FDA approval, DHTs enter the Current Procedural Terminology, Relative Value Scale Update Committee, and Centers for Medicare & Medicaid Services coding and valuation processes leading to coverage and payment decisions. DHT adoption is challenged by rapid technologic advancements, an inconsistent evidence base, marketing discrepancies, ambiguous coding guidance, and variable health insurance coverage. Regulators, policymakers, and payers will need to develop better methods to evaluate these promising technologies and guide their deployment. This includes striking a balance between patient safety and clinical effectiveness versus promotion of innovation, especially as DHTs increasingly incorporate artificial intelligence. Data validity, cybersecurity, risk management, societal, and ethical responsibilities should be addressed. Regulatory advances can support adoption of these promising tools by ensuring DHTs are safe, effective, accessible, and equitable. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF